Haematology 2018

• Phase II single-arm monotherapy study in patients with R/R iNHL • Accrual completed October 2012 • Tumour assessments: - Week 0, 8, 16, 24, 36 and 48, then every 12 weeks thereafter - Evaluated by independent review committee (IRC) - 2 radiologists with adjudication, if needed, and clinical review • Primary endpoint: Overall response rate (ORR) • Secondary endpoints: Duration of response (DOR), progression-free survival (PFS), safety Idelalisib in Double-Refractory iNHL

Study 101-09

Long-term follow-up

Week

0

48

Continuous therapy

Therapy maintained until progression

N=125

Idelalisib 150mg BID

Gopal A et al. ASH 2014, Abstract #1708